But for some RA sufferers, the anti-TNF drugs are not effective. Thus, there is clearly a need for additional agents to treat RA. Two new drugs, rituximab and abatacept, have recently been tested in Phase II trials and appear to provide effective alternatives.Abatacept competes with naturally occurring so−called proinflammatory proteins.